PDE7 inhibitors have been studied as possible inhibitors of T lymphocyte proliferation [17] and promoters of oligodendrocyte survival and proliferation, thus showing a high potential for the treatment of MS [18]; additionally, they have been studied as neuroprotective drugs for the treatment of Parkinson’s disease [19]. Here, PDE7A is linked to myeloid sarcoma.